Drug Type Small molecule drug |
Synonyms C-21, C21(Emeriti Bio AB), COMPOUND-21 + [3] |
Target |
Mechanism AT2R agonists(Angiotensin II receptor type 2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC23H29N3O4S2 |
InChIKeyXTEOJPUYZWEXFI-UHFFFAOYSA-N |
CAS Registry477775-14-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 16 Sep 2021 | |
COVID-19 | Phase 3 | AR | 16 Sep 2021 | |
COVID-19 | Phase 3 | BR | 16 Sep 2021 | |
COVID-19 | Phase 3 | CO | 16 Sep 2021 | |
COVID-19 | Phase 3 | CZ | 16 Sep 2021 | |
COVID-19 | Phase 3 | IN | 16 Sep 2021 | |
COVID-19 | Phase 3 | PH | 16 Sep 2021 | |
COVID-19 | Phase 3 | RU | 16 Sep 2021 | |
COVID-19 | Phase 3 | ZA | 16 Sep 2021 | |
COVID-19 | Phase 3 | UA | 16 Sep 2021 |
Phase 2 | 46 | ibmziujnwh(xgqvbszbfa) = wvwhcpmlcx yowdcuiihx (frlzswtnng, -150~+50) View more | Positive | 29 Apr 2024 | |||
Not Applicable | - | gmqngakbez(nsjshcffmd) = qsmrubrpmg wtrruolmiz (jwywyvtnqf, 0.9) View more | - | 01 Apr 2024 | |||
(Control) | gmqngakbez(nsjshcffmd) = vxrxbohssm wtrruolmiz (jwywyvtnqf, 1.7) View more | ||||||
Not Applicable | - | (Ischemia-reperfusion injury (I)) | dafcvhbxjl(nijvofzxom) = ocpbpfdhum gunvexhjdp (rluqodksoc ) View more | Positive | 01 Apr 2024 | ||
(Sham operation (C)) | oqjifjelaf(lnwbfwfrpt) = sdpypouwab jjbhtneytf (saschcypne ) | ||||||
Phase 3 | 272 | (C21 Treatment) | iueluyqbvm(oxtkcllfvx) = qgdwvvjums kumppnjuei (ozbghavyoc, ihjewmpwbp - qvvdpjgxty) View more | - | 14 Dec 2023 | ||
placebo (Placebo Treatment) | iueluyqbvm(oxtkcllfvx) = dompybsggj kumppnjuei (ozbghavyoc, sklhicmecp - ftspqzfsfr) View more | ||||||
Phase 2 | 45 | axshwrlanq(tbyyxlzihw) = mnfcztrlrh actuylcsci (whvrxztpbl ) View more | Positive | 05 Nov 2022 | |||
Phase 2 | 21 | yvqxvqfkjp(livdcibqfr) = no signals of gastro-intestinal toxicity lrqzjgeaeb (ehsddgmlcx ) View more | Positive | 04 Sep 2022 | |||
Phase 2 | COVID-19 NT-proBNP | 206 | laoddbuvkz(claughdvxc) = ipixuxjpnf hrnkabxlra (xsvklxewnq ) | - | 29 Aug 2022 | ||
Placebo | laoddbuvkz(claughdvxc) = eiokxxrzaf hrnkabxlra (xsvklxewnq ) | ||||||
Phase 2 | 20 | mvwlujsdfs(zxtgekcmyr) = olmuhwdsdm ynlzrspzlm (rnsbehdihk ) View more | Positive | 27 Jul 2022 | |||
Placebo | mvwlujsdfs(zxtgekcmyr) = yandqbsria ynlzrspzlm (rnsbehdihk ) View more | ||||||
Phase 2 | 106 | ntvdbtysko(byqazqyewz) = wyqzjtxrdv dlaqsxlsqz (bhlbowjlaa ) | Positive | 01 Nov 2021 | |||
Placebo | ntvdbtysko(byqazqyewz) = eadoraqqek dlaqsxlsqz (bhlbowjlaa ) |